Radioiodine treatment for benign thyroid diseases

Clinical Endocrinology

Volumn 66, Issue 6, 2007, Pages 757-764

  Weetman, Anthony P ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTITHYROID AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBIMAZOLE; LEVOTHYROXINE; LITHIUM; PREDNISOLONE; PROPYLTHIOURACIL; RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN; THIAMAZOLE;

ARTICLE; BENIGN TUMOR; CANCER RISK; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EYE DISEASE; GOITER; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; PRIORITY JOURNAL; RISK FACTOR; THYROID DISEASE; TREATMENT INDICATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTITHYROID AGENTS; CHILD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; IODINE RADIOISOTOPES; LITHIUM; RADIOPHARMACEUTICALS; RECOMBINANT PROTEINS; THYROID DISEASES; THYROTROPIN;

EID: 34347388660     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2007.02841.x     Document Type: Article

References (76)

1. Farrar, J.J. Toft, A.D. (1991) Iodine-131 treatment of hyperthyroidism: current issues. Clinical Endocrinology, 35, 207 212.
2. Hegedüs, L., Bonnema, S.J. Bennedbaek, F.N. (2003) Management of simple nodular goiter: current status and future perspectives. Endocrine Reviews, 24, 102 132.
3. Hedley, A.J., Lazarus, J.H., McGhee, S.M., Jones, R.B., Sharp, P.F., Naven, L.M., Beardwell, C.G. Hall, R. (1992) Treatment of hyperthyroidism by radioiodine. Summary of a UK national survey prepared for the Royal College of Physicians Committee on Endocrinology and Diabetes. Journal of the Royal College of Physicians of London, 26, 348 351.
4. Lazarus, J.H. (1995) Guidelines for the use of radioiodine in the management of hyperthyroidism: a summary. The Radioiodine Audit Subcommittee of the Royal College of Physicians Committee on Diabetes and Endocrinology, and the Research Unit of the Royal College of Physicians. Journal of the Royal College of Physicians of London, 29, 464 469.
5. Guidelines. The Use of Radioiodine in the Management of Benign Thyroid Disease. The Royal College of Physicians of London (in press).
6. Weetman, A.P. (2000) Graves' disease. New England Journal of Medicine, 343, 1236 1248.
7. Cooper, D.S. (2003) Hyperthyroidism. Lancet, 362, 459 468.
8. Rivkees, S.A., Sklar, C. Freemark, M. (1998) The management of Graves' disease in children, with special emphasis on radioiodine treatment. Journal of Clinical Endocrinology and Metabolism, 83, 3767 3776.
9. Rivkees, S. (2004) Radioactive iodine use in childhood Graves' disease: time to wake up and smell the I-131. Journal of Clinical Endocrinology and Metabolism, 89, 4227 4228.
10. Read, C.H. Jr., Tansey, M.J. Menda, Y. (2004) A 36-year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves' patients. Journal of Clinical Endocrinology and Metabolism, 89, 4229 4233.
11. Clark, J.D., Gelfand, M.J. Elgazzar, A.H. (1995) Iodine-131 therapy of hyperthyroidism in pediatric patients. Journal of Nuclear Medicine, 36, 442 445.
12. Surks, M.I., Ortiz, E., Daniels, G.H., Sawin, C.T., Col, N.F., Cobin, R.H., Franklyn, J.F., Hershman, J.M., Burman, K.D., Denke, M.A., Gorman, C., Cooper, R.S. Weissman, N.J. (2004) Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. Journal of the American Medical Association, 291, 228 238.
13. Faber, J., Jensen, I.W., Petersen, L., Nygaard, B., Hegedüs, L. Siersbaek-Nielsen, K. (1998) Normalization of serum thyrotrophin by means of radioiodine treatment in subclinical hyperthyroidism: effect on bone loss in postmenopausal women. Clinical Endocrinology, 48, 285 290.
14. The Administration of Radioactive Substances Advisory Committee 2006) Notes for Guidance on the Clinical Administration of Radiopharmaceuticals and Use of Sealed Radioactive Sources - March 2006. URL: http://www.arsac.org.uk/ notes_for_guidence/index.htm (accessed 1 October 2006).
15. Vanderpump, M.P., Ahlquist, J.A., Franklyn, J.A. Clayton, R.N. (1996) Consensus statement for good practice and audit measures in the management of hypothyroidism and hyperthyroidism. The Research Unit of the Royal College of Physicians of London, the Endocrinology and Diabetes Committee of the Royal College of Physicians of London, and the Society for Endocrinology. British Medical Journal, 313, 539 544.
16. Jarløv, V.A.E., Hegedüs, L., Kristensen, L.O., Nygaard, B. Hansen, J.M. (1995) Is calculation of the dose in radioiodine therapy of hyperthyroidism worthwhile? Clinical Endocrinology, 43l, 325 329.
17. Leslie, W.D., Ward, L., Salamon, E.A., Ludwig, S., Rowe, R.C. Cowden, E.A. (2003) A randomized comparison of radioiodine doses in Graves' hyperthyroidism. Journal of Clinical Endocrinology and Metabolism, 88, 978 983.
18. Catargi, B., Leprat, F., Guyot, M., Valli, N., Ducassou, D. Tabarin, A. (1999) Optimized radioiodine therapy of Graves' disease: analysis of the delivered dose and of other possible factors affecting outcome. European Journal of Endocrinology, 141, 117 121.
19. Alexander, E.K. Larsen, P.R. (2002) High dose of 131I therapy for the treatment of hyperthyroidism caused by Graves' disease. Journal of Clinical Endocrinology and Metabolism, 87, 1073 1077.
20. Allahabadia, A., Daykin, J., Sheppard, M.C., Gough, S.C. Franklyn, J.A. (2001) Radioiodine treatment of hyperthyroidism-prognostic factors for outcome. Journal of Clinical Endocrinology and Metabolism, 86, 3611 3617.
21. Kaptein, E.M., Levenson, H., Siegel, M.E., Gadallah, M. Akmal, M. (2000) Radioiodine dosimetry in patients with end-stage renal disease receiving continuous ambulatory peritoneal dialysis therapy. Journal of Clinical Endocrinology and Metabolism, 85, 3058 3064.
22. McDermott, M.T., Kidd, G.S., Dodson, L.E. Jr. Hofeldt, F.D. (1983) Radioiodine-induced thyroid storm. Case report and literature review. American Journal of Medicine, 75, 353 359.
23. Cooper, D.S. (1994) Antithyroid drugs and radioiodine therapy: a grain of (iodized) salt. Annals of Internal Medicine, 121, 612 613.
24. Burch, H.B., Solomon, B.L., Cooper, D.S., Ferguson, P., Walpert, N. Howard, R. (2001) The effect of antithyroid drug pretreatment on acute changes in thyroid hormone levels after 131I ablation for Graves' disease. Journal of Clinical Endocrinology and Metabolism, 86, 3016 3021.
25. Andrade, V.A., Gross, J.L. Maia, A.L. (2001) The effect of methimazole pretreatment on the efficacy of radioactive iodine therapy in Graves' hyperthyroidism: one-year follow-up of a prospective, randomized study. Journal of Clinical Endocrinology and Metabolism, 86, 3488 3493.
26. Imseis, R.E., Vanmiddlesworth, L., Massie, J.D., Bush, A.J. Vanmiddlesworth, N.R. (1998) Pretreatment with propylthiouracil but not methimazole reduces the therapeutic efficacy of iodine-131 in hyperthyroidism. Journal of Clinical Endocrinology and Metabolism, 83, 685 687.
27. Tuttle, R.M., Patience, T. Budd, S. (1995) Treatment with propylthiouracil before radioactive iodine therapy is associated with a higher treatment failure rate than therapy with radioactive iodine alone in Graves' disease. Thyroid, 5, 243 247.
28. Bonnema, S.J., Bennedbaek, F.N., Veje, A., Marving, J. Hegedüs, L. (2004) Propylthiouracil before 131I therapy of hyperthyroid diseases: effect on cure rate evaluated by a randomized clinical trial. Journal of Clinical Endocrinology and Metabolism, 89, 4439 4444.
29. Sabri, O., Zimny, M., Schulz, G., Schreckenberger, M., Reinartz, P., Willmes, K. Buell, U. (1999) Success rate of radioiodine therapy in Graves' disease: the influence of thyrostatic medication. Journal of Clinical Endocrinology and Metabolism, 84, 1229 1233.
30. Bonnema, S.J., Bennedbaek, F.N., Gram, J., Veje, A., Marving, J. Hegedüs, L. (2003) Resumption of methimazole after 131I therapy of hyperthyroid diseases: effect on thyroid function and volume evaluated by a randomized clinical trial. European Journal of Endocrinology, 140, 485 492.
31. Bogazzi, F., Bartalena, L., Brogioni, S., Scarcello, G., Burelli, A., Campomori, A., Manetti, L., Rossi, G., Pinchera, A. Martino, E. (1999) Comparison of radioiodine with radioiodine plus lithium in the treatment of Graves' hyperthyroidism. Journal of Clinical Endocrinology and Metabolism, 84, 499 503.
32. Bogazzi, F., Bartalena, L., Campomori, A., Brogioni, S., Traino, C., De Martino, F., Rossi, G., Lippi, F., Pinchera, A. Martino, E. (2002) Treatment with lithium prevents serum thyroid hormone increase after thionamide withdrawal and radioiodine therapy in patients with Graves' disease. Journal of Clinical Endocrinology and Metabolism, 87, 4490 4495.
33. Bal, C.S., Kumar, A. Pandey, R.M. (2002) A randomized controlled trial to evaluate the adjuvant effect of lithium on radioiodine treatment of hyperthyroidism. Thyroid, 12, 399 405.
34. Aizawa, Y., Yoshida, K., Kaise, N., Fukazawa, H., Kiso, Y., Sayama, N., Hori, H. Abe, K. (1997) The development of transient hypothyroidism after iodine-131 treatment in hyperthyroid patients with Graves' disease: prevalence, mechanism and prognosis. Clinical Endocrinology, 46, 1 5.
35. Michelangeli, V.P., Poon, C., Topliss, D.J. Colman, P.G. (1995) Specific effects of radioiodine treatment on TSAb and TBAb levels in patients with Graves' disease. Thyroid, 5, 171 176.
36. Chiovato, L., Fiore, E., Vitti, P., Rocchi, R., Rago, T., Dokic, D., Latrofa, F., Mammoli, C., Lippi, F., Ceccarelli, C. Pinchera, A. (1998) Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage. Journal of Clinical Endocrinology and Metabolism, 83, 40 46.
37. Teng, W.P., Stark, R., Munro, A.J., Young, S.M., Borysiewicz, L.K. Weetman, A.P. (1990) Peripheral blood T cell activation after radioiodine treatment for Graves' disease. Acta Endocrinologica, 122, 233 240.
38. Chiovato, L., Santini, F., Vitti, P., Bendinelli, G. Pinchera, A. (1994) Appearance of thyroid stimulating antibody and Graves' disease after radioiodine therapy for toxic nodular goitre. Clinical Endocrinology, 40, 803 806.
39. Tallstedt, L., Lundell, G., Torring, O., Wallin, G., Ljunggren, J.G., Blomgren, H. Taube, A. (1992) Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. New England Journal of Medicine, 326, 1733 1738.
40. Bartalena, L., Marcocci, C., Bogazzi, F., Manetti, L., Tanda, M.L., Dell'Unto, E., Bruno-Bossio, G., Nardi, M., Bartolomei, M.P., Lepri, A., Rossi, G., Martino, E. Pinchera, A. (1998) Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. New England Journal of Medicine, 338, 73 78.
41. Bartalena, L., Marcocci, C., Tanda, M.L., Manetti, L., Dell'Unto, E., Bartolomei, M.P., Nardi, M., Martino, E. Pinchera, A. (1998) Cigarette smoking and treatment outcomes in Graves ophthalmopathy. Annals of Internal Medicine, 129, 632 635.
42. Gorman, C.A. (1995) Therapeutic controversies. Radioiodine therapy does not aggravate Graves' ophthalmopathy. Journal of Clinical Endocrinology and Metabolism, 80, 340 342.
43. Tallstedt, L., Lundell, G., Blomgren, H. Bring, J. (1994) Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine treatment? European Journal of Endocrinology, 130, 494 497.
44. Kung, A.W., Yau, C.C. Cheng, A. (1994) The incidence of ophthalmopathy after radioiodine therapy for Graves' disease: prognostic factors and the role of methimazole. Journal of Clinical Endocrinology and Metabolism, 79, 542 546.
45. Weetman, A.P. Wiersinga, W.M. (1998) Current management of thyroid-associated ophthalmopathy in Europe. Results of an international survey. Clinical Endocrinology, 49, 21 28.
46. Ron, E., Doody, M.M., Becker, D.V., Brill, A.B., Curtis, R.E., Goldman, M.B., Harris, B.S., 3rd, Hoffman, D.A., McConahey, W.M., Maxon, H.R., Preston-Martin, S., Warshauer, M.E., Wong, F.L. Boice, J.D. Jr. (1998) Cancer mortality following treatment for adult hyperthyroidism. Cooperative Thyrotoxicosis Therapy Follow-up Study Group. Journal of the American Medical Association, 280, 347 355.
47. Hall, P., Lundell, G. Holm, L.E. (1993) Mortality in patients treated for hyperthyroidism with iodine-131. Acta Endocrinologica, 128, 230 234.
48. Franklyn, J.A., Maisonneuve, P., Sheppard, M., Betteridge, J. Boyle, P. (1999) Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population-based cohort study. Lancet, 353, 2111 2115.
49. Holm, L.E., Hall, P., Wiklund, K., Lundell, G., Berg, G., Bjelkengren, G., Cederquist, E., Ericsson, U.B., Hallquist, A. Larsson, L.G. (1991) Cancer risk after iodine-131 therapy for hyperthyroidism. Journal of the National Cancer Institute, 83, 1072 1077.
50. Robertson, J.S. Gorman, C.A. (1976) Gonadal radiation dose and its genetic significance in radioiodine therapy of hyperthyroidism. Journal of Nuclear Medicine, 17, 826 830.
51. Evans, P.M., Webster, J., Evans, W.D., Bevan, J.S. Scanlon, M.F. (1998) Radioiodine treatment in unsuspected pregnancy. Clinical Endocrinology, 48, 281 283.
52. Barrington, S.F., O'Doherty, M.J., Kettle, A.G., Thomson, W.H., Mountford, P.J., Burrell, D.N., Farrell, R.J., Batchelor, S., Seed, P. Harding, L.K. (1999) Radiation exposure pf the families of outpatients treated with radioiodine (iodine-131) for hyperthyroidism. European Journal of Nuclear Medicine, 26, 686 669.
53. Gangopadhyay, K.K., Sundram, F. De, P. (2006) Triggering radiation alarms after radioiodine treatment. British Medical Journal, 333, 293 4.
54. Bonnema, S.J., Bennedbaek, F.N., Wiersinga, W.M. Hegedüs, L. (2000) Management of the nontoxic multinodular goitre: a European questionnaire study. Clinical Endocrinology, 53, 5 12.
55. Bonnema, S.J., Bennedbaek, F.N., Ladenson, P.W. Hegedüs, L. 2002) Management of the nontoxic multinodular goiter: a North American survey. Journal of Clinical Endocrinology and Metabolism, 87, 112 117.
56. Berghout, A., Wiersinga, W.M., Drexhage, H.A., Smits, N.J. Touber, J.L. (1990) Comparison of placebo with 1-thyroxine alone or with carbimazole for treatment of sporadic non-toxic goitre. Lancet, 336, 193 197.
57. Lima, N., Knobel, M., Cavaliere, H., Sztejnsznajd, C., Tomimori, E. Medeiros-Neto, G. (1997) Levothyroxine suppressive therapy is partially effective in treating patients with benign, solid thyroid nodules and multinodular goiters. Thyroid, 7, 691 697.
58. Wesche, M.F., Tiel, V., Lips, P., Smits, N.J. Wiersinga, W.M. (2001) A randomized trial comparing levothyroxine with radioactive iodine in the treatment of sporadic nontoxic goiter. Journal of Clinical Endocrinology and Metabolism, 86, 998 1000.
59. Hegedüs, L., Nygaard, B. Hansen, J.M. (1999) Is routine thyroxine treatment to hinder postoperative recurrence of nontoxic goiter justified? Journal of Clinical Endocrinology and Metabolism, 84, 756 760.
60. Rojdmark, J. Jarhult, J. (1995) High long-term recurrence rate after subtotal thyroidectomy for nodular goitre. European Journal of Surgery, 161, 725 727.
61. Berghout, A., Wiersinga, W.M., Drexhage, H.A., van Trotsenburg, P., Smits, N.J., van der Gaag, R.D. Touber, J.L. (1989) The long-term outcome of thyroidectomy for sporadic non-toxic goitre. Clinical Endocrinology, 31, 193 199.
62. Bistrup, C., Nielsen, J.D., Gregersen, G. Franch, P. (1994) Preventive effect of levothyroxine in patients operated for non-toxic goitre: a randomized trial of one hundred patients with nine years follow-up. Clinical Endocrinology, 40, 323 327.
63. Le Moli, R., Wesche, M.F., Tiel-Van Buul, M.M. Wiersinga, W.M. (1999) Determinants of long-term outcome of radioiodine therapy of sporadic non-toxic goitre. Clinical Endocrinology, 50, 783 789.
64. Hegedüs, L., Hansen, B.M., Knudsen, N. Hansen, J.M. (1988) Reduction of size of thyroid with radioactive iodine in multinodular non-toxic goitre. British Medical Journal, 297, 661 662.
65. Nygaard, B., Hegedüs, L., Gervil, M., Hjalgrim, H., Soe-Jensen, P. Hansen, J.M. (1993) Radioiodine treatment of multinodular non-toxic goitre. British Medical Journal, 307, 828 832.
66. Wesche, M.F., Tiel-v-Buul, M.M., Smits, N. Wiersinga, W.M. (1995) Reduction in goiter size by 131I therapy in patients with non-toxic multinodular goiter. European Journal of Endocrinology, 132, 86 87.
67. Huysmans, D.A., Hermus, A.R., Corstens, F.H., Barentsz, J.O. Kloppenborg, P.W. (1994) Large, compressive goiters treated with radioiodine. Annals of Internal Medicine, 121, 757 762.
68. Bonnema, S.J., Bertelsen, H., Mortensen, J., Andersen, P.B., Knudsen, D.U., Bastholt, L. Hegedüs, L. (1999) The feasibility of high dose iodine 131 treatment as an alternative to surgery in patients with a very large goiter: effect on thyroid function and size and pulmonary function. Journal of Clinical Endocrinology and Metabolism, 84, 3636 3641.
69. Howarth, D.M., Epstein, M.T., Thomas, P.A., Allen, L.W., Akerman, R. Lan, L. (1997) Outpatient management of patients with large multinodular goitres treated with fractionated radioiodine. European Journal of Nuclear Medicine, 24, 1465 1469.
70. Nielsen, V.E., Bonnema, S.J., Boel-Jorgensen, H., Veje, A., Hegedüs, L. (2005) Recombinant human thyrotropin markedly changes the 131I kinetics during 131I therapy of patients with nodular goiter: an evaluation by a randomized double-blinded trial. Journal of Clinical Endocrinology and Metabolism, 90, 79 83.
71. Nieuwlaat, W.A., Huysmans, D.A., van den Bosch, H.C., Sweep, C.G., Ross, H.A., Corstens, F.H. Hermus, A.R. (2003) Pretreatment with a single, low dose of recombinant human thyrotropin allows dose reduction of radioiodine therapy in patients with nodular goiter. Journal of Clinical Endocrinology and Metabolism, 88, 3121 3129.
72. Silva, M.N., Rubio, I.G., Romao, R., Gebrin, E.M., Buchpiguel, C., Tomimori, E., Camargo, R., Cardia, M., S. Medeiros-Neto, G. (2004) Administration of a single dose of recombinant human thyrotrophin enhances the efficacy of radioiodine treatment of large compressive multinodular goitres. Clinical Endocrinology, 60, 300 308.
73. Nielsen, V.E., Bonnema, S.J. Hegedüs, L. (2006) Transient goiter enlargement after administration of 0.3 mg of recombinant human thyrotropin in patients with benign nontoxic nodular goiter: a randomized, double-blind, crossover trial. Journal of Clinical Endocrinology and Metabolism, 91, 1317 1322.
74. Nielsen, V.E., Bonnema, S.J., Boel-Jorgensen, H., Grupe, P. Hegedus, L. (2006) Stimulation with 0.3-mg recombinant human thyrotropin prior to iodine 131 therapy to improve the size reduction of benign nontoxic nodular goiter: a prospective randomized double-blind trial. Archives of Internal Medicine, 166, 1476 1482.
75. Schmidt, M., Gorbauch, E., Dietlein, M., Faust, M., Stutzer, H., Eschner, W., Theissen, P. Schicha, H. (2006) Incidence of postradioiodine immunogenic hyperthyroidism/Graves' disease in relation to a temporary increase in thyrotropin receptor antibodies after radioiodine therapy for autonomous thyroid disease. Thyroid, 16, 281 288.
76. Nygaard, B., Knudsen, J.H., Hegedüs. L., Scient, A.V. Hansen, J.E. (1997) Thyrotropin receptor antibodies and Graves' disease, a side effect of 131I treatment in patients with nontoxic goiter. Journal of Clinical Endocrinology and Metabolism, 82, 2926 2930.